NEW YORK (GenomeWeb News) – Qiagen will use a database and software, as well as clinical samples, from the Center for Molecular Medicine in research aimed at developing biomarkers for breast cancer and other women’s health issues, the company said today.
 
The agreement gives Qiagen access to CMM’s XenoBase software and database, which was developed by CMM’s partner, the Van Andel Research Institute, to “identify clinically actionable associations between diseases, biomarkers and treatments,” the company said. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.